Gender differences in subjective discontinuation symptoms associated with ketamine use

Substance Abuse: Treatment, Prevention, and Policy

Volumn 9, Issue 1, 2014, Pages

  Chen, Wen Yin ^a   Huang, Ming Chyi ^a,b   Lin, Shih Ku ^a,b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Discontinuance symptoms; Epidemiology; Gender difference; Ketamine

Indexed keywords

ANALGESIC AGENT; KETAMINE;

ADDICTION; ADOLESCENT; ADULT; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; SEX DIFFERENCE; TAIWAN; WITHDRAWAL SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; QUESTIONNAIRES; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TAIWAN; YOUNG ADULT;

EID: 84908127088     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-9-39     Document Type: Article

References (46)

1. White PFWW, Trevor AJ. Ketamine-its pharmacology and therapeutic uses. Anesthesiology 1982, 56:119-136. 10.1097/00000542-198202000-00007, 6892475.
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47(4):351-354. 10.1016/S0006-3223(99)00230-9, 10686270.
3. Morgan CJ, Curran HV. Ketamine use: a review. Addiction 2011, 107(1):27-38.
4. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl) 2006, 188(4):408-424. 10.1007/s00213-006-0572-3, 17006715.
5. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010, 105(1):121-133. 10.1111/j.1360-0443.2009.02761.x, 19919593.
6. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction 2006, 101(8):1212-1213. 10.1111/j.1360-0443.2006.01494.x, 16869851.
7. Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J 2003, 44(1):31-34.
8. Blachut M, Solowiow K, Janus A, Ruman J, Cekus A, Matysiakiewicz J, Hese RT. [A case of ketamine dependence]. Psychiatr Pol 2009, 43(5):593-599.
9. Petersen RC SR, Stillman RC. Phencyclidine: an overview. NIDA Res Monogr 1978, 21:1-17.
10. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry 1994, 151(5):779.
11. Jansen KL, rracotCankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs 2001, 33(2):151-158. 10.1080/02791072.2001.10400480, 11476262.
12. Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004, 99(11):1450-1461. 10.1111/j.1360-0443.2004.00879.x, 15500598.
13. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 2008, 95(3):219-229. 10.1016/j.drugalcdep.2008.01.024, 18355990.
14. Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003, 69(1):23-28. 10.1016/S0376-8716(02)00243-0, 12536063.
15. Cheng WC, Ng KM, Chan KK, Mok VK, Cheung BK. Roadside detection of impairment under the influence of ketamine-evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci Int 2007, 170(1):51-58. 10.1016/j.forsciint.2006.09.001, 17046188.
16. Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 2010, 16(1):6-11.
17. Fang YX, Wang YB, Shi J, Liu ZM, Lu L. Recent trends in drug abuse in China. ActaPharmacol Sin 2006, 27(2):140-144.
18. The United Nations Office on Drugs and Crime (UNODC) World Drug Report 2013, United Nations publication(Sales No. E.13.XI.6), The United Nations Office on Drugs and Crime (UNODC).
19. Chen WJ, Fu TC, Ting TT, Huang WL, Tang GM, Hsiao CK, Chen CY. Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004-2006. BMC Public Health 2009, 9:27. 10.1186/1471-2458-9-27, 2636802, 19159468.
20. Lua AC, Lin HR, Tseng YT, Hu AR, Yeh PC. Profiles of urine samples from participants at rave party in Taiwan: prevalence of ketamine and MDMA abuse. Forensic Sci Int 2003, 136(1-3):47-51. 10.1016/S0379-0738(03)00261-5, 12969619.
21. Yen CF, Hsu SY, Cheng CP. Polysubstance use and its correlates in adolescent ecstasy users in Taiwan. Addict Behav 2007, 32(10):2286-2291. 10.1016/j.addbeh.2007.01.022, 17314013.
22. Leung KS, Li JH, Tsay WI, Callahan C, Liu SF, Hsu J, Hoffer L, Cottler LB. Dinosaur girls, candy girls, and Trinity: voices of Taiwanese club drug users. J Ethn Subst Abuse 2008, 7(3):237-257. 10.1080/15332640802313205, 2596647, 19042808.
23. Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. J Addict Dis 2010, 29(2):127-138. 10.1080/10550881003684582, 20407972.
24. Randall CL, Roberts JS, Del Boca FK, Carroll KM, Connors GJ, Mattson ME. Telescoping of landmark events associated with drinking: a gender comparison. J Stud Alcohol 1999, 60(2):252-260.
25. Bradley KA, Badrinath S, Bush K, Boyd-Wickizer J, Anawalt B. Medical risks for women who drink alcohol. J Gen Intern Med 1998, 13(9):627-639. 10.1046/j.1525-1497.1998.cr187.x, 1497016, 9754520.
26. Anker JJ, Carroll ME. Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr Top Behav Neurosci 2011, 8:73-96.
27. Fattore L, Fadda P, Fratta W. Sex differences in the self-administration of cannabinoids and other drugs of abuse. Psychoneuroendocrinology 2009, 34(Suppl 1):S227-S236.
28. Medina KL, Shear PK, Corcoran K. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective. J Int Neuropsychol Soc 2005, 11(6):753-765.
29. van der Plas EA, Crone EA, van den Wildenberg WP, Tranel D, Bechara A. Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. J Clin Exp Neuropsychol 2009, 31(6):706-719. 10.1080/13803390802484797, 2829119, 19037812.
30. Winters WD, Hance AJ, Cadd GC, Lakin ML. Seasonal and sex influences on ketamine-induced analgesia and catalepsy in the rat; a possible role for melatonin. Neuropharmacology 1986, 25(10):1095-1101. 10.1016/0028-3908(86)90156-5, 3785578.
31. Lees J, Hallak JE, Deakin JF, Dursun SM. Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol 2004, 18(3):337-339. 10.1177/026988110401800302, 15358976.
32. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001, 895(1-2):264-267. 10.1016/S0006-8993(01)02079-0, 11259788.
33. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013, 64:452-463. 3445733, 22735770.
34. Ng CM, Ma WK, To KC, Yiu MK. The Chinese version of the pelvic pain and urgency/frequency symptom scale: a useful assessment tool for street-ketamine abusers with lower urinary tract symptoms. Hong Kong Med J 2012, 18(2):123-130.
35. Kushner L, Moldwin RM. Efficiency of questionnaires used to screen for interstitial cystitis. J Urol 2006, 176(2):587-592. 10.1016/j.juro.2006.03.035, 16813894.
36. Rabiner EA. Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?. J Psychopharmacol 2007, 21(3):253-258. 10.1177/0269881107077767, 17591653.
37. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992, 260(3):1209-1213.
38. Carrier N, Kabbaj M. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 2013, 70:27-34.
39. Zhang Y, Lu C, Zhang J, Hu L, Song H, Li J, Kang L. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. Addict Behav 2013, 38(1):1424-1430. 10.1016/j.addbeh.2012.06.024, 23006246.
40. Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 2012, 110(11):1762-1766. 10.1111/j.1464-410X.2012.11028.x, 22416998.
41. Lee CJ, Do BR, Kim JK, Yoon YD. Pentobarbital and ketamine suppress serum concentrations of sex hormones in the female rat. J Anesth 2000, 14(4):187-190. 10.1007/s005400070003, 14564563.
42. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am 2010, 33(2):339-355. 10.1016/j.psc.2010.01.004, 3124962, 20385341.
43. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independentmood and anxiety disorders: Results from the national epidemiologic survey on alcohol and relatedconditions. Arch Gen Psychiatry 2004, 61(8):807-816. 10.1001/archpsyc.61.8.807, 15289279.
44. Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med 1998, 60(2):150-155. 10.1097/00006842-199803000-00006, 9560862.
45. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010, 113(3):678-684.
46. Garg A, Sinha P, Kumar P, Prakash O. Use of naltrexone in ketamine dependence. Addict Behav 2014, 39(8):1215-1216. 10.1016/j.addbeh.2014.04.004, 24813545.